Table 2 Confirmed antitumor activity, assessed by RECIST v1.1

From: Transarterial chemoembolization plus atezolizumab and bevacizumab in patients with intermediate hepatocellular carcinoma: a single-arm, phase 2 trial

Variables

All patients per investigator review (n = 45)

Objective response ratea

21 (47%, ≥36%)

 Complete response

3 (7%, ≥3%)

 Partial response

18 (40%, ≥30%)

 Stable disease

23 (51%, ≥41%)

 Progressive disease

1 (2%, ≥0.2%)

Disease control rateb

39 (87%, 73–95)

Median time to response, weeks (IQR)

11.9 (10.1–19.8)

Median duration of response, weeks (IQR)

36.6 (14.9–46.9)

Duration of response ≥3 months

21 (47%)

Duration of response ≥6 months

13 (29%)

  1. ORR, CR, PR, SD, and PD are described as n (%, ≥ one-sided 90% CI) of 45 patients; DCR is described as n (%, two-sided 95% CI)
  2. RECIST response evaluation criteria in solid tumors
  3. aComplete response or partial response for at least 4 weeks
  4. bComplete response, partial response, or stable disease for at least 6 months
Back to article page